Jessica Bishop
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by UCB, Inc. at 46.7% of the total. Among medical clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 503 payments — averaging $119.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$28K
- Neurelis, Inc.$14K
- SK Life Science, Inc.$5K
- Jazz Pharmaceuticals Inc.$4K
- Livanova USA, Inc.$4K
- Catalyst Pharmaceuticals, Inc.$3K
- plus $3K from 17 others
What the payments were for
- Consulting fees$18,33231%
- Speaking & faculty fees$25,99343%
- Travel & lodging$6,77011%
- Food & beverage$8,75915%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 120 | $28,038 |
| Neurelis, Inc. | 59 | $13,925 |
| SK Life Science, Inc. | 110 | $5,189 |
| Jazz Pharmaceuticals Inc. | 22 | $3,853 |
| Livanova USA, Inc. | 49 | $3,629 |
| Catalyst Pharmaceuticals, Inc. | 22 | $2,588 |
| AbbVie | 33 | $789 |
| Eisai Inc. | 23 | $675 |
| Amgen | 8 | $237 |
| Pfizer | 12 | $186 |
| Sunovion Pharmaceuticals Inc. | 14 | $159 |
| Teva Pharmaceuticals USA, Inc. | 2 | $141 |
| Immedica Pharma US, Inc. | 5 | $134 |
| Greenwich Biosciences, Inc. | 6 | $95 |
| Sumitomo Pharma America, Inc. | 4 | $86 |
| Neurocrine Biosciences, Inc. | 4 | $85 |
| Zogenix Inc. | 3 | $64 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Biocodex, Inc. | 1 | $27 |
| Acadia Pharmaceuticals Inc | 1 | $26 |
| Medtronic | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nayzilam$16,974
- VALTOCO$13,202
- Briviact$4,468
- Epidiolex$3,396
- XCOPRI$3,000
- Fycompa$2,435
- VNS Therapy$1,778
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$1,350
How this compares
$59,998 in reported general payments places this provider in the 95th percentile of 265 medical providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 858 | $1,408,410 |
| BriviactBrivaracetam | 469 | $706,155 |
| EpidiolexCannabidiol (Cbd) | 86 | $621,408 |
| OnfiClobazam | 131 | $522,433 |
| FycompaPerampanel | 374 | $474,163 |
| VimpatLacosamide | 270 | $424,244 |
| FinteplaFenfluramine Hcl | 21 | $407,226 |
| AptiomEslicarbazepine Acetate | 112 | $260,805 |
| Lamictal XrLamotrigine | 86 | $200,530 |
| NayzilamMidazolam | 181 | $170,255 |
| Lacosamide | 760 | $162,410 |
| Lamotrigine ErLamotrigine | 234 | $98,776 |
| ValtocoDiazepam | 98 | $88,745 |
| Keppra XrLevetiracetam | 45 | $88,183 |
| Clobazam | 437 | $84,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Fintepla, Nayzilam | $28,038 | $1,707,880941 claims |
| SK Life Science, Inc.Xcopri | $5,189 | $1,408,410858 claims |
| Eisai Inc.Fycompa | $675 | $474,163374 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $159 | $260,805112 claims |
| Neurelis, Inc.Valtoco | $13,925 | $88,74598 claims |
| PfizerNurtec Odt, Lyrica | $186 | $46,28931 claims |
| AbbVieQulipta | $789 | $33,97632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 medical providers in Idaho.
Other medical in Boise
- Cali BradberryBoise$9K
- Sharene WatsenBoise$7K
- Zana DelicBoise$4K
- Jacob TebbsBoise$3K
- Ronnie IsaacsonBoise$3K
- Scott AstleyBoise$3K
- Shawna BeechinorBoise$2K
- Melissa KroonBoise$2K
- Dillon SmithBoise$2K
- Jessie ZimmermanBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.